Modra Pharmaceuticals

Executive Summary

Modra Pharmaceuticals is a Netherlands-based biotech company pioneering oral taxane therapy through its proprietary boosted oral drug absorption platform. Founded in 2015, the company aims to replace intravenous docetaxel with its lead candidate, ModraDoc006/r, an oral tablet designed to improve bioavailability, safety, and patient convenience. Currently in Phase 2 clinical development, ModraDoc006/r addresses a significant unmet need in oncology by enabling at-home administration, potentially reducing hospital visits and enhancing quality of life for patients. The platform's ability to modulate oral absorption of taxanes differentiates it from conventional formulations and positions Modra to capture a share of the multibillion-dollar taxane market.

Upcoming Catalysts (preview)

• H2 2026Phase 2 clinical data readout for ModraDoc006/r60% success
• 2027Strategic partnership or licensing deal for commercialization40% success
• H1 2027Regulatory guidance from EMA on Phase 3 trial design70% success